Research programme: anti-angiogenesis antibodies - Bionomics/Genmab

Drug Profile

Research programme: anti-angiogenesis antibodies - Bionomics/Genmab

Latest Information Update: 22 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bionomics; Genmab
  • Class Antibodies
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Feb 2008 This programme is still in active development
  • 13 Feb 2006 Eight protein targets have been exclusively licensed to Genmab A/S worldwide
  • 04 Apr 2002 Preclinical trials in Cancer in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top